- Home
- QLGN vs TCRT Comparison
QLGN vs TCRT Comparison
Compare QLGN & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- TCRT
- Stock Information
- Founded
- QLGN 1996
- TCRT 1998
- Country
- QLGN United States
- TCRT United States
- Employees
- QLGN N/A
- TCRT N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- TCRT Health Care
- Exchange
- QLGN Nasdaq
- TCRT Nasdaq
- Market Cap
- QLGN 2.4M
- TCRT 2.5M
- IPO Year
- QLGN N/A
- TCRT N/A
- Fundamental
- Price
- QLGN $3.32
- TCRT $3.94
- Analyst Decision
- QLGN
- TCRT
- Analyst Count
- QLGN 0
- TCRT 0
- Target Price
- QLGN N/A
- TCRT N/A
- AVG Volume (30 Days)
- QLGN 111.5K
- TCRT 946.1K
- Earning Date
- QLGN 04-15-2025
- TCRT 05-14-2025
- Dividend Yield
- QLGN N/A
- TCRT N/A
- EPS Growth
- QLGN N/A
- TCRT N/A
- EPS
- QLGN N/A
- TCRT N/A
- Revenue
- QLGN N/A
- TCRT $10,000.00
- Revenue This Year
- QLGN N/A
- TCRT $5,680,500.00
- Revenue Next Year
- QLGN N/A
- TCRT N/A
- P/E Ratio
- QLGN N/A
- TCRT N/A
- Revenue Growth
- QLGN N/A
- TCRT 100.00
- 52 Week Low
- QLGN $2.96
- TCRT $1.31
- 52 Week High
- QLGN $29.45
- TCRT $18.50
- Technical
- Relative Strength Index (RSI)
- QLGN 44.88
- TCRT 85.08
- Support Level
- QLGN $3.06
- TCRT $1.31
- Resistance Level
- QLGN $3.78
- TCRT $1.60
- Average True Range (ATR)
- QLGN 0.28
- TCRT 0.27
- MACD
- QLGN 0.03
- TCRT 0.16
- Stochastic Oscillator
- QLGN 19.80
- TCRT 87.12
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.